The report provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects.
Browse the Full Report @ http://www.orbisresearch.com/reports/index/fallopian-tube-cancer-pipeline-review-h1-2016 .
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Check the Discount for this Report @ http://www.orbisresearch.com/contacts/discount/144102 .
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.
– The report provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer
– The report reviews pipeline therapeutics for Fallopian Tube Cancer by companies and universities/research institutes based on information derived from company and
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration
details & other developmental activities
– The report reviews key players involved Fallopian Tube Cancer therapeutics and enlists all their major and minor projects
– The report assesses Fallopian Tube Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer
Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Fallopian Tube Cancer
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Fallopian Tube Cancer pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Request a Sample of this Report @ http://www.orbisresearch.com/contacts/request-sample/144102 .
AB Science SA
AbGenomics International, Inc.
ADC Therapeutics Sarl
Advenchen Laboratories, LLC
Aslan Pharmaceuticals Pte. Ltd.
Astellas Pharma Inc.
Atara Biotherapeutics, Inc.
Azaya Therapeutics, Inc.
Basilea Pharmaceutica AG
Betta Pharmaceuticals Co. Ltd.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Celldex Therapeutics, Inc.
Cellectar Biosciences, Inc.
Celon Pharma Sp. z o.o.
Cerulean Pharma, Inc.
Chipscreen Biosciences Ltd
Chugai Pharmaceutical Co., Ltd.
DAE HWA Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
Deciphera Pharmaceuticals, LLC
Dr. Reddy’s Laboratories Limited
Eli Lilly and Company
Esperance Pharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Frost Biologic, Inc.
Galena Biopharma, Inc.
Gilead Sciences, Inc.
Green Cross Corporation
Halozyme Therapeutics, Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Hetero Drugs Limited
Horizon Pharma Plc
Hutchison MediPharma Limited
Innovent Biologics, Inc.
INSYS Therapeutics, Inc.
ISU ABXIS Co.,Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Kanion Pharmaceutical Co., Ltd.
Johnson & Johnson
KaloBios Pharmaceuticals, Inc.
Karyopharm Therapeutics, Inc.
Kolltan Pharmaceuticals, Inc.
Kuhnil Pharmaceutical Co., Ltd.
Kyowa Hakko Kirin Co., Ltd.
LegoChem Biosciences, Inc
Les Laboratoires Servier SAS
Mebiopharm Co., Ltd.
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
Mersana Therapeutics, Inc.
Millennium Pharmaceuticals, Inc.
Molecular Targeting Technologies, Inc.
NanoCarrier Co., Ltd.
OBI Pharma, Inc.
Omnitura Therapeutics Inc.
Oncolys BioPharma Inc.
Oncolytics Biotech Inc.
OncoTherapy Science, Inc.
Ono Pharmaceutical Co., Ltd.
Panacea Biotec Limited
Pharma Mar, S.A.
Puma Biotechnology, Inc.
Rexahn Pharmaceuticals, Inc.
Richter Gedeon Nyrt.
Sareum Holdings Plc
Shanghai Henlius Biotech Co., Ltd.
Shionogi & Co., Ltd.
Sihuan Pharmaceutical Holdings Group Ltd.
Simcere Pharmaceutical Group
Sorrento Therapeutics, Inc.
Spectrum Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc.
Supratek Pharma Inc.
Synta Pharmaceuticals Corp.
Synthon Holdings BV
Taiho Pharmaceutical Co., Ltd.
Takeda Pharmaceutical Company Limited
Tara Immuno-Oncology Therapeutics LLC
TG Therapeutics, Inc.
ViiV Healthcare Limited
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019